hydrochlorothiazide (Microzide, Hydrodiuril)
Title: hydrochlorothiazide (Microzide, Hydrodiuril)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/5/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 5, 2019 Category: Cardiology Source Type: news

losartan and hydrochlorothiazide (Hyzaar)
Title: losartan and hydrochlorothiazide (Hyzaar)Category: MedicationsCreated: 3/12/2000 12:00:00 AMLast Editorial Review: 3/4/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 4, 2019 Category: Cardiology Source Type: news

Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 60 lots of Losartan potassium tablets USP and 54 lots of Losartan potassium/ hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 1, 2019 Category: Food Science Source Type: news

Lowering BP, Lipids in Healthy Elderly Has No Cognitive Effect
WEDNESDAY, Feb. 27, 2019 -- Candesartan plus hydrochlorothiazide, rosuvastatin, or their combination do not impact cognitive decline among older people, according to a study published online Feb. 27 in Neurology. Jackie Bosch, Ph.D., from McMaster... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2019 Category: Pharmaceuticals Source Type: news

Another Drug Company Recalls Tainted Losartan Another Drug Company Recalls Tainted Losartan
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of losartan potassium and hydrochlorothiazide combination tablets owing to the presence of a probable carcinogen.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 25, 2019 Category: Food Science Source Type: news

Torrent Recalls Six More Lots of Tainted Losartan Tablets Torrent Recalls Six More Lots of Tainted Losartan Tablets
The company has recalled a total of 16 lots of losartan potassium and hydrochlorothiazide combination tablets because of the presence of a probable carcinogen.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 22, 2019 Category: Food Science Source Type: news

Heart Drug Recall Expanded Again
(CNN) — The recall of popular heart drugs has expanded yet again. The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes. This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Recall Valsartan Source Type: news

Class 2 Medicines Recall: Actavis Group PTC EHF - recall of some batches of Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets and Irbesartan/Hydrochlorothiazide 150/12.5mg Film-coated Tablets
Specific batches of Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets and Irbesartan/Hydrochlorothiazide 150/12.5mg Film-coated Tablets, made by Actavis (now Accord), are being recalled as (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - January 3, 2019 Category: Drugs & Pharmacology Source Type: news

Mylan Expands Recall to All Unexpired Lots of Valsartan in US Mylan Expands Recall to All Unexpired Lots of Valsartan in US
The latest recall stems from NDEA contamination and includes 26 lots of amlodipine/valsartan tablets, 51 lots of valsartan tablets, and 27 lots of valsartan/hydrochlorothiazide tablets.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths). (Source: Food a...
Source: Food and Drug Administration - December 4, 2018 Category: Food Science Source Type: news

Teva Recalls Two Blood Pressure Medications
FRIDAY, Nov. 30, 2018 -- All lots of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination blood pressure tablets have been recalled by Teva Pharmaceuticals due to higher-than-acceptable levels of a chemical that may cause... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2018 Category: Pharmaceuticals Source Type: news

Teva Recalls All Amlodipine/Valsartan Combination Products in US Teva Recalls All Amlodipine/Valsartan Combination Products in US
In the ongoing saga of tainted sartans, Teva recalls all amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide combination products because of contamination with NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets (see table below) due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. The impurity found in Mylan ’s valsartan API is known as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen. This chemical is typically found in very small amounts in certain foods, drinking water, air pollution, a...
Source: Food and Drug Administration - November 27, 2018 Category: Food Science Source Type: news

Mylan Recalls 15 Lots of Valsartan Products in US Mylan Recalls 15 Lots of Valsartan Products in US
The Mylan recall of valsartan tablets, amlodipine/valsartan tablets, and valsartan/hydrochlorothiazide tablets marks the latest recall of sartans contaminated with probable carcinogens.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in...
Source: Food and Drug Administration - November 21, 2018 Category: Food Science Source Type: news

Another Tainted'Sartan' Recalled for Impurity Another Tainted'Sartan' Recalled for Impurity
Sandoz, along with FDA, has recalled one lot of losartan potassium hydrochlorothiazide tablets because of the presence of the probable human carcinogen NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

MHRA Drug Safety Update: Hydrochlorothiazide: risk of non-melanoma skin cancer particularly in long-term use
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 15, 2018 Category: Drugs & Pharmacology Source Type: news

Blood Pressure Drug Recall Expands Again; Meds May Be Tainted With Cancer-Causing Chemical
(CNN) — The US Food and Drug Administration says another heart medicine is being voluntarily recalled after tests showed that it was tainted with a potential cancer-causing chemical. The recall includes one lot of Sandoz’s losartan potassium hydrochlorothiazide 100 milligram/25 milligram tablets with the lot number JB8912. Patients use these drugs to keep their high blood pressure in check. The drug is being recalled because the active ingredient has tested positive for N-Nitrosodiethylamine or NDEA, a suspected human and animal carcinogen that is used in gasoline as a stabilizer for industry materials and as a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 12, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Local TV Valsartan Source Type: news

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinoge...
Source: Food and Drug Administration - November 9, 2018 Category: Food Science Source Type: news

Diovan HCT (Valsartan and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2018 Category: Drugs & Pharmacology Source Type: news

Drug Recalls: Accord Hydrochlorothiazide and Children's Advil Suspension Bubble Gum Flavored
Label Mix-up Spurs Recall of Accord Blood Pressure Meds One lot of high blood pressure medication is being recalled after a labeling mix-up, Accord Healthcare Inc. says. The recall is for 100-count bottles of hydrochlorothiazide tablets USP, 12.5... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 30, 2018 Category: General Medicine Source Type: news

RECALL: Blood Pressure Meds Contain Wrong Drug
Accord Healthcare has recalled one lot of 12.5-milligram hydrochlorothiazide tablets because the 100-count bottle was discovered to contain 100 spironolactone tablets. (Source: WebMD Health)
Source: WebMD Health - August 29, 2018 Category: Consumer Health News Source Type: news

Label Mix-Up Spurs Recall of Accord Blood Pressure Meds
WEDNESDAY, Aug. 29, 2018 -- One lot of high blood pressure medication is being recalled after a labeling mix-up, Accord Healthcare Inc. has announced. The recall is for 100-count bottles of hydrochlorothiazide tablets USP, 12.5 mg, lot PW05264. One... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 29, 2018 Category: Pharmaceuticals Source Type: news

Blood Pressure Drug Recalled For Possible Life-Threatening Label Error
(CBS Local) – A potentially life-threatening label mix-up has led to a nationwide recall of a high blood pressure medication, according to the U.S. Food and Drug Administration. Accord Healthcare Inc. is voluntarily recalling one lot of 12.5 mg hydrochlorothiazide tablets after a 100-count bottle of the drug was found to contain 100 tablets of another drug, spironolactone. Accord Healthcare is recalling some bottles of Hydrochlorothiazide tablets USP, 12.5 mg, which is prescribed for high blood pressure, because they may contain the wrong pills.  Photo Credit- ACCORD HEALTHCARE Both medications are used t...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 29, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News blood pressure FDA Local TV Recall talkers Source Type: news

A High Blood Pressure Medication Is Being Recalled After a Potentially ‘Life-Threatening’ Labeling Mistake
A potentially “life-threatening” labeling mix-up spurred a nationwide recall of a high blood pressure medication, the Food and Drug Administration (FDA) announced. Accord Healthcare is voluntarily recalling a single lot of 12.5-milligram hydrochlorothiazide tablets, after a pharmacy reported finding a 100-count bottle that actually contained spironolactone tablets, according to the FDA. The rest of the lot (PW05264) has been recalled due to the “potential mix-up of labeling,” but Accord says the remainder of its drugs are unaffected. Both hydrochlorothiazide and spironolactone can be used to treat ...
Source: TIME: Health - August 29, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Recalls Source Type: news

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up
A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 28, 2018 Category: Food Science Source Type: news

Prinzide (Lisinopril and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2018 Category: Drugs & Pharmacology Source Type: news

Atacand to be divested to Cheplapharm in Europe
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension. (Source: World Pharma News)
Source: World Pharma News - July 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets
Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical. The impurity detected in the API is N- nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International ...
Source: Food and Drug Administration - July 17, 2018 Category: Food Science Source Type: news

3 Companies Recall Blood Pressure Medications Over Cancer Fears
Some drugs used to control high blood pressure and prevent heart failure were voluntarily recalled this past week due to an impurity that could possibly lead to cancer, the U.S. Food and Drug Administration said. These products — with the active ingredient valsartan, a generic drug used to treat high blood pressure — may contain N-nitrosodimethylamine (NDMA), a possible human carcinogen. The FDA asked three companies, Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd., to recall their valsartan products. Solco and Teva were also asked to recall their drugs containing valsartan/hydr...
Source: TIME: Health - July 17, 2018 Category: Consumer Health News Authors: Jennifer Calfas Tags: Uncategorized medicine onetime Source Type: news

FDA Recalls Common Heart Drug For Potential Cancer Risk
(CNN) — The recall of a common drug used to control blood pressure and help prevent heart failure was announced by the US Food and Drug Administration on Friday, a week after 22 other countries recalled it because the drug contains a chemical that poses a potential cancer risk. Valsartan is off patent and is used as a component of other generic medicines, but not all medicines containing the ingredient are involved, according to the FDA. The US recall includes the the versions of valsartan that are made by Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd. as well as valsartan/hydrochlor...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 16, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Valsartan Source Type: news

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products
Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product lots. This impurity has been classified as a probable human carcinogen as per International Agency for Research on Ca...
Source: Food and Drug Administration - July 13, 2018 Category: Food Science Source Type: news

Class 1 Medicines Recall: Action Now including out of hours Pharmacy Level Recall: Superseded drug alert - Valsartan/Hydrochlorothiazide 160/12.5mg Film-Coated Tablets
The Medicines& Healthcare products Regulatory Agency (MHRA) issued a Class 1 Medicines Recall (Drug Alert EL (18)A/11) on 5th July 2018. Pharmacies in the UK were asked to recall all batches of v (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 11, 2018 Category: Drugs & Pharmacology Source Type: news

Hydrochlorothiazide and Risk of Hearing Disorder Hydrochlorothiazide and Risk of Hearing Disorder
While ototoxicity is not a known adverse effect of hydrochlorothiazide, this case series suggest there might be a causal relationship between its use and hearing disorder.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2018 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Olmesartan Medoxomil and Hydrochlorothiazide Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 21, 2018 Category: Drugs & Pharmacology Source Type: news

Possible Link Between Hydrochlorothiazide and Malignant Melanoma Possible Link Between Hydrochlorothiazide and Malignant Melanoma
Long-term hydrochlorothiazide use appears to be associated with an increased risk of malignant melanoma, researchers from Denmark report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hydrochlorothiazide Tied to Increased Melanoma Risk
(MedPage Today) -- Possible link pronounced for lentigo and nodular subtypes (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 29, 2018 Category: Dermatology Source Type: news

Hydrochlorothiazide and Lisinopril Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

Hydrochlorothiazide and Skin Cancer: Raise the Red Flag Hydrochlorothiazide and Skin Cancer: Raise the Red Flag
A dramatic association has been found between this common diuretic and nonmelanoma skin cancer.Medscape Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2018 Category: Consumer Health News Tags: Dermatology Viewpoint Source Type: news

Triamterene and Hydrochlorothiazide Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 23, 2018 Category: Drugs & Pharmacology Source Type: news

Hydrochlorothiazide and Skin Cancer: Should We Be Worried? Hydrochlorothiazide and Skin Cancer: Should We Be Worried?
Should we be concerned about, or take any action on, a new link found between this common antihypertensive agent and skin cancer?Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 12, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Hydrochlorothiazide May Up Basal, Squamous Cell Cancer Risk
Increased risk for basal cell carcinoma, squamous cell carcinoma, with dose - response relationship (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 6, 2018 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Research Finds Popular Blood Pressure Drug Increases Skin Cancer Risk
This study shows a possible link between HCTZ and basal cell and squamous cell carcinomas of the skin. These are not melanomas, the deadliest form of skin cancer, but they both can pose serious health risks. This study shows an association between HCTZ and skin cancer, not proof that the medication actually causes cancer, but it’s link that needs to be studied further. In the meantime, continue to take your blood pressure medication and protect yourself from excessive sun exposure. (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 6, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Dr. Mallika Marshall Source Type: news

Medical News Today: Common blood pressure drug raises skin cancer risk
New research shows that people who take the popular hypertension drug hydrochlorothiazide may put themselves at a dramatically high risk of skin cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 6, 2017 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news